Search Ontology:
ChEBI

N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide

Term ID
CHEBI:146263
Synonyms
  • (3aS,4S,6aR)-N-[25-[[O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-O-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl]oxy]-21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacos-1-yl]hexahydro-2-oxo-1H-thieno[3,4-d]imidaz
  • 3-(21-biotinamino-4,7,10,13,16,19-hexaoxagenicaminoamino)-propyl 2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranoside
  • N-(3-{[2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl-(1->4)-2-amino-2-deoxy-alpha-D-galactopyranosyl]oxy}propyl)-23-oxo-27-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]-4,7,10,13,16,19-hexaoxa-22-az
  • N-(3-{[alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxaheptacosan-1-amide
Definition
A trisaccharide derivative in which alpha-D-galactosaminyl-(1->4)-alpha-D-galactosaminyl-(1->4)-alpha-D-galactosamine is linked glycosidically to biotin via a (21-oxo-3,6,9,12,15,18-hexaoxa-22-azapentacosan-1-yl)amino spacer. One of a set of synthesised biotinylated oligo-alpha-(1->4)-D-galactosamines comprising from two to six monosaccharide units, along with their N-acetylated derivatives (PMID:31913631), aimed at analysing the specificity of the antibody responses to a complex exopolysaccharide galactosaminogalactan found in Aspergillus fumigatus, the most important airborne human fungal pathogen in industrialized countries.
References
Ontology
ChEBI  ( EBI )
Relationships
is a type of
Phenotype
Phenotype resulting from N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Phenotype where environments contain N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Phenotype modified by environments containing N-(3-{[alpha-D-GalN-(1->4)-alpha-D-GalN-(1->4)-alpha-D-GalN-yl]oxy}propyl)-21-(biotinylamino)-4,7,10,13,16,19-hexaoxadodecan-1-amide
Human Disease Model